ResearcherMayo ClinicActive in the last 2 years
Catherine E. Hagen
Matched on ORCID iD 0000-0002-1867-4957; OpenAlex author ID A5014534264. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 29
2019: 2 papers · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper
Papers 5
- Emerin is an effector of oncogenic KRAS-driven nuclear dynamics in pancreatic cancer. Co-author DOI 10.1172/jci.insight.187799↗
- Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.anndiagpath.2020.151485↗
- Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003049↗
- Coexisting pancreatic serous cystadenoma and pancreatic ductal adenocarcinoma: A cytological-pathologic correlation with literature review. Co-author DOI 10.1016/j.anndiagpath.2019.07.006↗
- Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Co-author DOI 10.1016/j.surg.2019.05.010↗
Closest collaborators
The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mohammed Aldakkak · 3 shared papers, 2019–2020 · strength 0.30
- Paper Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant t… DOI 10.1016/j.anndiagpath.2020.151485↗
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Paper Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. DOI 10.1016/j.surg.2019.05.010↗
- Douglas B. Evans · 3 shared papers, 2019–2020 · strength 0.30
- Paper Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant t… DOI 10.1016/j.anndiagpath.2020.151485↗
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Paper Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. DOI 10.1016/j.surg.2019.05.010↗
- Susan Tsai · 3 shared papers, 2019–2020 · strength 0.30
- Paper Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant t… DOI 10.1016/j.anndiagpath.2020.151485↗
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Paper Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. DOI 10.1016/j.surg.2019.05.010↗
- Kathleen K. Christians · 3 shared papers, 2019–2020 · strength 0.30
- Paper Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant t… DOI 10.1016/j.anndiagpath.2020.151485↗
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Paper Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. DOI 10.1016/j.surg.2019.05.010↗
- Daniel J. Rowan · 2 shared papers, 2019–2020 · strength 0.26
- Paper Coexisting pancreatic serous cystadenoma and pancreatic ductal adenocarcinoma: A cytological-pathologic correlation wit… DOI 10.1016/j.anndiagpath.2019.07.006↗
- Paper Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant t… DOI 10.1016/j.anndiagpath.2020.151485↗
- Renzo Emanuel Vera · 1 shared paper, 2025 · strength 0.19
- Ezequiel J. Tolosa · 1 shared paper, 2025 · strength 0.19
- Brooke R Tader · 1 shared paper, 2025 · strength 0.19
- Aleksey V. Matveyenko · 1 shared paper, 2025 · strength 0.19
- Luis F. Flores · 1 shared paper, 2025 · strength 0.19
- Kayla C. LaRue-Nolan · 1 shared paper, 2025 · strength 0.19
- Rondell Patrell Graham · 1 shared paper, 2025 · strength 0.19
- David R Pease · 1 shared paper, 2025 · strength 0.19
- Ryan Michael Carr · 1 shared paper, 2025 · strength 0.19
- Christopher L. Pin · 1 shared paper, 2025 · strength 0.19
- David W. Dawson · 1 shared paper, 2025 · strength 0.19
- Martín E. Fernández-Zapico · 1 shared paper, 2025 · strength 0.19
- Chad A. Barnes · 2 shared papers, 2019–2020 · strength 0.18
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Paper Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. DOI 10.1016/j.surg.2019.05.010↗
- Paul S. Ritch · 2 shared papers, 2019–2020 · strength 0.18
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Paper Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. DOI 10.1016/j.surg.2019.05.010↗
- Bradley A. Erickson · 2 shared papers, 2019–2020 · strength 0.18
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Paper Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. DOI 10.1016/j.surg.2019.05.010↗
- William Adrian Hall · 2 shared papers, 2019–2020 · strength 0.18
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Paper Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. DOI 10.1016/j.surg.2019.05.010↗
- Ben George · 2 shared papers, 2019–2020 · strength 0.18
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Paper Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. DOI 10.1016/j.surg.2019.05.010↗
- Kulwinder S. Dua · 2 shared papers, 2019–2020 · strength 0.18
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Paper Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. DOI 10.1016/j.surg.2019.05.010↗
- Tamara Giorgadze · 1 shared paper, 2019 · strength 0.14
- Christopher Hartley · 1 shared paper, 2020 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.